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Abstract. Chemerin is adipokine that plays an important role in macrophage infiltration 
into adipose tissue and may contribute to inflammation development and insulin resistance. 
This study aimed to determine the effect of lifestyle modification with and without 
metformin on chemerin in metabolic syndrome. Forty-five metabolic syndrome subjects 
(IDF-2005) were randomly assigned to one of the two groups: placebo group (n=22) and 
metformin group (n=23). Both groups underwent a 12-week lifestyle modification (diet and 
moderate aerobic-exercise). Only 40 participants (placebo group n=20 and metformin 
group n=20) completed the survey whereas 5 participants dropped out of the study. After 
their lifestyle was modified, body weight, BMI, WC, and chemerin decreased significantly 
(p<0.001) in both groups. Moreover, there was a significant difference between both groups 
in body weight, BMI, and WC (p<0.05) but not for chemerin. Thus, lifestyle modification 
with metformin improved BW, BMI, WC on metabolic syndrome, and there was no 
decrease significantly of chemerin between placebo and metformin groups. Further 
investigations should be done to confirm the effect of lifestyle modification and metformin 
on chemerin after an extended follow-up period. 
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Abstrak. Chemerin adalah adipokin yang memainkan peran penting dalam infiltrasi 
makrofag ke dalam jaringan adiposa dan dapat berkontribusi pada perkembangan 
peradangan dan resistensi insulin. Penelitian ini bertujuan untuk mengetahui pengaruh 
modifikasi gaya hidup dengan dan tanpa metformin pada chemerin pada sindrom 
metabolik. Empat puluh lima subyek sindrom metabolik (IDF-2005) secara acak 
ditugaskan ke salah satu dari dua kelompok: kelompok plasebo (n = 22) dan kelompok 
metformin (n = 23). Kedua kelompok menjalani modifikasi gaya hidup 12 minggu (diet dan 
olahraga aerobik sedang). Hanya 40 peserta (kelompok plasebo n = 20 dan kelompok 
metformin n = 20) menyelesaikan survei sedangkan 5 peserta keluar dari penelitian. 
Setelah gaya hidup mereka dimodifikasi, berat badan, BMI, WC, dan chemerin menurun 
secara signifikan (p <0,001) pada kedua kelompok. Selain itu, ada perbedaan yang 
signifikan antara kedua kelompok dalam berat badan, BMI, dan WC (p <0,05) tetapi tidak 
untuk chemerin. Dengan demikian, modifikasi gaya hidup dengan metformin meningkatkan 
BW, BMI, WC pada sindrom metabolik, dan tidak ada penurunan chemerin yang signifikan 
antara kelompok plasebo dan metformin.Investigasi lebih lanjut harus dilakukan untuk 
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mengkonfirmasi pengaruh modifikasi gaya hidup dan metformin pada chemerin setelah 
periode tindak lanjut yang diperpanjang. 
Kata Kunci: Modifikasi Gaya Hidup, Sindrom Metabolik, Chemerin  
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1 Introduction 
Metabolic syndrome represents a combination of cardiometabolic risk factors and determinants 
including central adiposity, insulin resistance, glucose intolerance, dyslipidemia, non-alcoholic 
fatty liver disease, and hypertension. The prevalence of metabolic syndrome increases rapidly 
worldwide as a result of the continuous obesity epidemic. It will also have a risk on the global 
incidence of cardiovascular disease and T2D [1]. Adiposity has been identified as an important 
endocrine organ that does not only store energy but also regulates energy homeostasis and 
metabolism [2]. 
Chemerin was recently found as an adipokine, and its expression increased in obesity state [3,4]. 
Several specific functions of chemerin are including regulation of specific immune cell 
migration [4,5], anti-inflammatory effects on macrophages [6], and regulation of adipogenesis 
[5]. Previously, a significant association has been identified between circulating chemerin levels 
and characteristics of the metabolic syndrome in a relatively small sample of human subjects 
from Mauritius [3]. Bozaoglu et al, measured circulating chemerin levels in human subjects and 
found that plasma chemerin concentrations were strongly associated with BMI, plasma 
triglycerides, and blood pressure [7]. Metformin treatment decreases serum chemerin in women 
with PCOS [8]. 
Physical inactivity is known as the risk factor of type 2 diabetes mellitus (T2DM) [9], and 
aerobic training has been shown to reduce adiposity and insulin resistance in obese adults [10]. 
There has been no previous report about lifestyle modification induces changes in chemerin 
concentrations in metabolic syndrome, which may provide a link between obesity and insulin 
resistance. 
Lifestyle modification against overweight, physical inactivity, and atherogenic diet has been 
recommended as a basic in the management of metabolic syndrome [11]. However, only 
lifestyle modification is often unable to achieve clinically meaningful weight loss [12]. 
Metformin, a biguanide oral hypoglycemic agent has been shown to reduce weight, 
hyperinsulinemia, and hyperglycemia in adult patients with T2D [13]. Metformin also has been 
recently suggested to attenuate the insulin-sensitizing effect of exercise [14], inhibition of 
platelet aggregation, antioxidant activity, weight reduction, an effect on lipid parameters: total 
cholesterol, high density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol 
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(LDL-C), triglycerides (TG), and arterial hypertension [15,16]. Metformin can be given safely 
to euglycemic patients because it does not induce hypoglycemia [17]. 
Therefore, the aim of this study was to assess the effect of lifestyle modification with metformin 
on chemerin in metabolic syndrome. 
2 Method 
The research subjects were recruited in H. Adam Malik Hospital, Medan, Indonesia. From 184 
obese nurses (BMI ≥ 25), only 45 subjects were diagnosed with metabolic syndrome (IDF-
2005) and agreed to involve in lifestyle modification for 12 weeks. IDF-2005 guidelines for 
diagnosis of metabolic syndrome were used, namely central obesity with a WC of ≥ 90 cm for 
men and ≥ 80 cm for women (Asian population), and any two of the following four factors: (1) 
triglyceride ≥150 mg/dl or specific treatment for lipid abnormality; (2) HDL-C (men < 40 mg/dl 
and women <50 mg/dl) or specific treatment for lipid abnormality; (3) hypertension ≥ 130/85 
mmHg or treatment of previously diagnosed hypertension; and (4) FBS ≥ 100 mg/dl or 
previously diagnosed T2D [18,19]. They were assigned randomly to either the placebo group 
(n=22) or metformin group (n=23). 
All subjects gave their fully informed consent before participated in the study. The local Ethical 
Committee has approved the study. We excluded subjects who were smokers, had 
cardiovascular diseases or any other major illnesses or were taking medications that could affect 
the laboratory test results. Before and during the study, trained health nurses and participants 
discussed the lifestyle modification programs including diet and exercise. To facilitate 
behavioral change, each participant received a leaflet and diary to record their behavioral 
performance, diet, physical activity, WC, and body weight [BW] monitored by phone. 
Participants attended a follow-up meeting every week to confirm how the participants had 
complied with the targeted behaviors and checked whether the participants had experienced any 
health and safety problems related to behavioral changes including the side effect of drugs. 
2.1 Anthropometric 
Heights in meters (m) and weight in kilograms (kg) were measured, and BMI was also 
calculated as the weight in kilograms divided by the square of the height in meters. For the 
Asian population, BMI < 18.5 is classified as underweight, BMI 18.5-22.9 is classified as 
normal, BMI 23-24.9 is classified as overweight, BMI 25-29.9 is classified as obese I, and BMI 
≥ 30.0 is classified as obese II [18]. The waist circumference (WC) was measured midway 
between the uppermost border of the iliac crest and the lower border of the costal margin (rib 
cage), and Asian values (male ≥ 90 cm; female ≥ 80 cm) [18]. The exercise program consisted 
of a moderate aerobic exercise for at least 3 times per week (30 minutes each) [20]. The aerobic 
exercise was supervised by a physiotherapist at each training session. The exercise group 
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performed a warm-up exercise for 5 min, followed by the main exercise for 20 min, and 
relaxation exercise for 5 min at the end of the exercise period [21]. 
2.2 Diet 
Between 0 and 12-week period throughout the study, all subjects followed a weight 
maintenance diet (55–60% carbohydrate, 15–20% protein, and 20–25% fat) [21]. All subjects 
were free to consume and choose the food according to their dietary habits and from the list of 
food replacement.  
2.3 Blood Pressure and Blood Sample Analysis 
Blood pressure was measured twice after a 10-min rest with the mercury sphygmomanometer 
and averaged. After overnight fasting and collection, blood samples were centrifuged for 15 min 
while plasma and serum containing tubes were stored at - 20 0C until analysis. Blood glucose 
levels were measured by photometer autoanalyzer Modular P 800, plasma HDL-C and LDL-C 
were measured by the Architect Ci 8200 (Abbott, USA), triglyceride was measured by GPO-
PAP methods of Architect, hs-CRP was measured by sensitive immunoassay (Siemens Medical 
Solution Inc, IL, USA) of Immulite 1000, HbA1c was measured by high-performance liquid 
chromatographic (HPLC) of the Bio-Rad D 10, and chemerin was measured by Mediagnost 
ELISA E-102 (Sandwich-Assay). 
3 Statistical Analysis 
Data were presented as mean ± SD. Normality assumption of the placebo group and metformin 
group data was evaluated and confirmed using Shapiro-Wilk in each group. Differences 
between and within each data of the placebo group and metformin group were tested using an 
independent sample t-test and dependent t-test. However, the abnormal data were tested using 
the Mann-Whitney U test and Wilcoxon test. Two-sided p-values of <0.05 were considered as 
statistically significant. The data were analyzed using SPSS software. 
4 Results 
Of the 45 participants at the baseline, 40 participants (placebo group, n=20; metformin group, 
n=20) completed in the 12-week survey, whereas 5 participants (2 participants from the placebo 
group and 3 participants from the metformin group) dropped out of the study.  
In Table 1, there was no significant difference in the baseline characteristics of the two groups.  
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Table 1 Clinical Characteristics of Placebo and Metformin Groups on Metabolic 
Syndrome Subjects 
Variable 
Placebo group 
Metformin 
group pa 
n=22 n=23 
n (F/M) 17/5 20/3  
Age (yr) 40.41±5.61 42.91±5.62 0.142 
BW (kg) 76.98±11.64 80.53±14.72 0.374 
BMI (kg/m2) 32.11±4.09 34.03±5.76 0.206 
WC (cm)  95.40±7.41 97.23±10.95 0.927 
SBP (mmHg)  123.18±11.29 125.21±19.74 0.567 
DBP (mmHg)  82.00±9.99 80.65±10.69 0.247 
HDL-C 
(mg/dl)  
45.72±8.48 48.34±15.47 0.918 
TG (mg/dl)  150.40±51.05 152.00±63.87 0.974 
FBG (mg/dl)  85.27±11.98 86.69±10,06 0.351 
PPG (mg/dl) 115.72±11.98 104.21±21.40 0.401 
hs-CRP 
(mg/dl) 
3.45±2.47 3.83±2.34 0.467 
Chemerin 
(ng/mL) 
344.09±104.58 345.15±83.90 0.970 
BW: body weight; BMI: Body Mass Index; CRP: C-reactive protein; DBP: Diastolic  
Blood Pressure: FBS: fasting Blood Sugar; PPG: Postprandial Glucose; SBP: Systolic  
Blood Pressure; TG: Triglyceride; WC: Waist Circumference; PPG: Postprandial glucose. aBased 
on an independent t-test. 
In Table 2, After 12 weeks of lifestyle modification, there was decrease significantly on BW, 
BMI, WC, SBP, and chemerin in both groups. There was no decrease significantly of chemerin 
on both groups. 
Table 2 Clinical Characteristics of Placebo and Metformin Groups after 12-Week 
Follow-Up for both Groups of Metabolic Syndrome Subjects 
  Placebo group Metformin group   
Variable (n=20) (n=20) Pd 
  
Baseline At 12-week 
Differ
encea 
Pb Baselinea At 12-week 
Differ
encea 
Pc 
  
Weight 
(kg) 
77.6 ± 11.0 75.2±10.8 -2.3 0.001** 81.4±14.6 77.4±14.5 -3.9 0.001** 0.001** 
BMI 
(kg/m2) 
32.1 ± 4.1 30.9±4.1 -1.1 0.001** 34.2±5.6 32.4±5.6 -1.8 0.001** 0.002** 
WC (cm)  95.7 ± 7.3 89.9±7.5 -5.8 0.001** 97.9±11.5 91.8±10.7 -6.2 0.001** 0.047* 
SBP 
(mmHg)  
123.5±11.4 114.0±8.2 -9.5 0.007** 127.0±20.3 112.8±8.5 -14.3 0.001** 0.231 
DBP 
(mmHg)  
82.2±10.5 69.0±5.5 -31.8 0.001* 80.6±11.0 67.5±7.2 -13.3 0.001** 0.300 
HDL-C 
(mg/dl)  
46.4±8.5 45.3±10.0 -1.1 0.628 48.9±16.4 46.5±9.8 -2.4 0.653 0.103 
TG 
(mg/dl)  
147.5±50.5 153.3±67.9 5.8 0.634 152.3±66.9 149.0±102.4 -3.3 0.147 0.285 
FBS 83.4±10.6 91.7±20.64 8.3 0.001* 84.9±8.9 87.7±10.7 2.8 0.305 0.039* 
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BMI: Body Mass Index; CRP: C-reactive protein; DBP: Diastolic Blood Pressure: FBS: Fasting Blood Sugar; PPG; SBP: Systolic 
Blood Pressure; TG: Triglyceride; WC: Waist Circumference; 2h-PPG: 2 hour-Postprandial glucose. 
a Difference between the baseline and 12-week follow-up surveys 
b Difference between the baseline and 12-week follow-up surveys in the Placebo group, based on a dependent t-test. 
c Difference between the baseline and 12-week follow-up surveys in the Metformin group, based on a dependent t-test. 
d Δ Difference between the Placebo group and Metformin group after the 12-week follow-up surveys, based on an independent t-test. 
*P < 0.05, **P < 0.01 
5 Discussion 
Adipose tissue is an active organ which secretes many metabolically important proteins known 
as adipokines [22]. Some of these adipokines have important functions in insulin resistance and 
cardiovascular complications with central or visceral obesity [23]. A recent systematic review of 
literature promotes a dose-response effect of aerobic exercise on visceral adiposity, but the 
ability of exercise to reduce visceral adipose tissue was less strenuous in those with metabolic 
disorders [24]. Thus, it remains unclear whether a dose-response of exercise on central adiposity 
is also consistent in metabolic syndrome. Nevertheless, regular exercise has an important role in 
the abdominal fat loss during weight maintenance and can avoid weight gain in those who have 
successfully lost weight [25]. Chemerin may have a role in the metabolic syndrome and may be 
an independent promising adipokine marker.  
The study results of Saremi et al. showed that chemerin levels decreased significantly after body 
weight reduction (particularly visceral fat) in overweight and obese males after 12-week of 
aerobic training [26]. Similar results were recently presented in a large-scale epidemiological 
study from Mauritius [3]. 
According to these studies, lifestyle modification decreased BW, BMI, WC, DBP, and chemerin 
significantly in the placebo group and metformin group, whereas FBS and CRP only decreased 
significantly in the placebo group. However, there was no more effect of metformin on 
chemerin. 
Plasma CRP concentration is known to be a key index of systemic inflammation. Few previous 
studies have reported the effect of exercise training on CRP levels. Mattusch et al. found a 
significant reduction in CRP levels after nine months of marathon training in 12 athletes [27]. 
Furthermore, Smith et al. also reported lower CRP levels in 43 volunteers after six months of 
exercise training. Based on these studies, chemerin decreased more significantly than CRP, and 
the future chemerin might replace the position of CRP as the key index of systemic 
inflammation [28]. Thus, lifestyle modification with metformin improved BW, BMI, WC, and 
chemerin on metabolic syndrome. There was no decrease significantly of chemerin between 
placebo and metformin groups. However, the limitation of the study was the small sample size 
and a short duration of the study. 
(mg/dl)  
PPG 
(mg/dl) 
114.9±35.4 112.3±37.7 -2.5 0.717 105.1±22.4 102.3±19.3 -2.8 0.491 0.142 
CRP 
(mg/dl) 
3.6±2.5 3.0±2.2 -0.6 0.048* 3.9±2.4 3.5±1.9 -0.6 0.327 0.482 
Chemerin 
(ng/mL) 
339.5±106.6 225.5±43.7 -113.9 0.001** 339.9±82.9 226.5±46.1 -113.9 0.001** 0.430 
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6 Conclusion 
Lifestyle modification with metformin improved BW, BMI, WC on metabolic syndrome, and 
there was no significant decrease of chemerin between placebo and metformin groups. Further 
investigations should be done to confirm the effect of lifestyle modification and metformin on 
chemerin after an extended follow-up period. 
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